In 2011, the National Institute on Aging and Alzheimer’s Association (NIA-AA) proposed separate diagnostic recommendations for the preclinical mild cognitive impairment and dementia stages of Alzheimer’s disease based on different biomarkers able to discriminate, in vivo, the different pathological entities, including beta-amyloid deposition, pathologic tau and neurodegeneration. This evidence concerns the gene MAPT and dementia.